SLN
- Silence Therapeutics plc
()
Overview
Company Summary
Silence Therapeutics plc is a biotechnology company that specializes in the development of targeted RNA therapeutics. The company uses RNA interference (RNAi) technology, a biological process that selectively silences gene expression, to develop innovative drugs for the treatment of various diseases.
Silence Therapeutics focuses on creating therapies that address unmet medical needs by selectively inhibiting the production of disease-causing proteins. By targeting specific genes and blocking the expression of harmful proteins, the company aims to develop treatments for a range of conditions, including rare diseases, cancer, and cardiovascular disorders.
The company has developed a proprietary platform called AtuRNAi, which enables the design and development of highly specific RNAi molecules. These molecules work by interfering with the messenger RNA (mRNA) that carries genetic instructions from DNA to produce proteins. By disrupting this process, Silence Therapeutics aims to selectively prevent the production of disease-related proteins, ultimately inhibiting the progression or occurrence of diseases.
Silence Therapeutics collaborates with partners in both academia and the pharmaceutical industry to advance its pipeline of RNAi therapeutics. The company's approach involves rigorous research and development, preclinical and clinical studies, and regulatory submissions to ensure the safety and efficacy of its drug candidates.
In summary, Silence Therapeutics is focused on harnessing the power of RNA interference technology to develop targeted RNA therapeutics that can potentially revolutionize the treatment of various diseases.